<DOC>
	<DOC>NCT01512693</DOC>
	<brief_summary>This open-label, non-randomized study was designed to compare pharmacokinetics of a single 50 milligram (mg) dose of MK-0822 in participants with and without moderate hepatic insufficiency (abnormal liver function) in order to determine to what degree hepatic dysfunction may impact therapeutic blood levels of MK-0822.</brief_summary>
	<brief_title>Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Subjects With Moderate Hepatic Insufficiency (MK-0822-070)</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Not currently pregnant, nursing or planning to be pregnant throughout the course of the study; agree to use specified contraception per protocol requirement Body Mass Index (BMI) of â‰¤ 39 kg/m^2 (not obese) Judged to be in good health (for healthy participant population) Nonsmoker for the past 6months; social smokers (smoke less than 10 cigarettes within the past 3 months; or per discretion of the study Investigator, quit smoking within the past 3 months. Diagnosed with chronic (more than 6 months), stable (no acute episodes of illness within the previous 2 months) hepatic insufficiency (liver dysfunction) with features of cirrhosis due to any cause (for the moderate hepatic insufficiency participant population) Possess the ability to understand the study, grant voluntary informed consent and willingly comply with all study requirements Does not meet the age requirement, is mentally or legally incapacitated, has or is expected to have significant emotional problems, or a history of a clinically significant psychiatric disorder Has been diagnosed with a disease or medical condition which may pose a risk to the participant or may confound the study results Compromised renal (kidney) function, significant organ system disease(s) or cancer(s) Unable to refrain from or anticipates the use of any new medication, including prescription and nonprescription drugs or herbal remedies Meets the requirements of the study in regard to current medication profile including: prescribed medications, caffeine, alcohol, overthecounter drugs, herbals and nutritional products; with expected nonuse of recreational (illicit) drugs associated with misuse, abuse and/or addiction Had surgery, donated 1 unit of blood or received another investigational study medication within 4 weeks prior to the study's first dose of investigational product History of multiple and/or severe allergies, or has had a lifethreatening reaction or inability to tolerate prescription or nonprescription drugs or food</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>